Raul Pajuelo at Siegfried
Name: Raul Pajuelo
Company: Siegfried AG
Location: Zofingen, Aargau, Switzerland
Company Overview
Siegfried AG is a leading global contract development and manufacturing organization (CDMO) within the pharmaceutical industry. The company has over 150 years of experience and operates 13 production sites across three continents. Siegfried AG focuses on the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms, including both chemical and pharmaceutical products.
Siegfried's Key Services and Offerings
- Formulation Development
- Analytical Development
- Solid Dosage Forms
- Parenterals (vials, ampoules, cartridges, syringes)
- Ophthalmics (liquids and semisolids)
- Active Pharmaceutical Ingredient (API)
- Exclusive Synthesis
- High Potency & Intermediates
- Sterile Filling
- Biologics Finished Dosage Forms
- Spray Drying
Recent Corporate Developments
- September 2024: EGS Beteiligungen AG increased its shareholding in Siegfried to 7.2% registered shares by exercising a bond conversion right.
- August 2024: Siegfried opened a new quality control lab in Minden.
- July 2024: Marcel Imwinkelried appointed as the new CEO.
- July 2024: Siegfried completed the acquisition of an early-phase CDMO in Wisconsin, USA.
- April 2024: Siegfried announced changes in its management team.
- October 2023: New state-of-the-art R&D Center opened in Evionnaz, Switzerland.
Corporate Social Responsibility and Sustainability
Siegfried is committed to corporate social responsibility and sustainability, as evidenced by the awarding of the EcoVadis Gold Medal to the Barberà and El Masnou sites in Barcelona for their outstanding sustainability efforts. The company emphasizes integrating sustainability into all aspects of its operations.
Organizational Structure
Siegfried employs approximately 3,600 personnel across locations in Switzerland, Germany, France, Spain, Malta, China, and the USA. The company’s expertise spans formulation development, sterile filling, and high-potency API production, providing integrated solutions to clients in the pharmaceutical sector.
Conclusion
Raul Pajuelo's association with Siegfried places him within a company known for its robust and extensive pharmaceutical and chemical manufacturing capabilities. Siegfried's recent strategic advancements, including acquisitions and new facilities, underscore its commitment to growth and innovation.
For further details on Siegfried’s offerings and recent activities, prospective clients and partners can visit their [website](http://www.siegfried.ch) or reach out directly to their headquarters in Zofingen, Switzerland.